Cypralis Assets

There are three natural product classes known to potently inhibit cyclophilins: cyclosporins, peptolides, and sanglifehrins. Cypralis has generated novel derivatives and established IP from each of these classes. Besides being potent cyclophilin inhibitors, the compounds are mostly non-immunosuppressive and span a wide range of solubility and PK properties. The collection includes compounds that are suitable for intravenous injection/infusion, for oral and topical applications and have generally excellent drug properties. Notably, one class of compounds has been shown to penetrate the blood-brain barrier to give high brain levels in rodents after oral dosing. A preclinical program evaluates members of this compound family for the treatment of neurodegenerative and neuroinflammatory diseases.

The compound CC-4066 has just completed Phase I clinical trials as intravenous treatment and prevention of acute kidney injury associated with major surgery.

Cypralis has established extensive IP protection around these compounds and is using them as pharmacological tools for target validation studies and as starting points for medicinal chemistry programmes.